Medicare's Drug Plan Lifeline Snapped Early, Seniors Face Rising Premiums Post-2026

A voluntary Medicare program designed to keep prescription drug premiums for Part D plans stable is set to conclude after 2026, a full year earlier than initially anticipated

"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."

. This "Premium Stabilization Demonstration," implemented in response to cost volatility following the Inflation Reduction Act's benefit changes, aimed to smooth out premium increases for standalone prescription drug plans

"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."

. However, its early termination means seniors, particularly those with lower incomes who may not qualify for the highest levels of assistance, could face significantly higher monthly premiums starting in 2027

"Original Medicare enrollees could face higher monthly premiums for their stand-alone Part D drug plan coverage next year now that a pilot program designed to keep premiums in check will be discontinued."

. While the Centers for Medicare & Medicaid Services (CMS) touts its finalization of 2027 Medicare Advantage and Part D payment policies as strengthening accountability and long-term sustainability [c1, c2], the premature end of this stabilization effort raises concerns about the affordability and availability of Part D plans for a vulnerable population.

The Inflation Reduction Act (IRA) brought significant changes to Medicare Part D, including allowing Medicare to negotiate some drug prices and capping out-of-pocket costs. While beneficial for many, these sweeping changes also introduced unexpected volatility into the market for standalone prescription drug plans (PDPs), leading to unpredictable premium fluctuations for 2025 and beyond

"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."

. To counter this, the Centers for Medicare & Medicaid Services (CMS) launched the Part D Premium Stabilization Demonstration. This voluntary program, designed for PDPs, essentially acted as a buffer, absorbing some of the premium shockwaves. The fact that it's ending a year sooner than anticipated suggests either the volatility was more contained than feared, or, more likely, that the program's cost to the government or its complexity led to an early sunset. The Sierra Sun Times noted CMS's announcement regarding the finalization of 2027 Medicare Advantage and Part D payment policies, which included the conclusion of this demonstration

Centers for Medicare & Medicaid Services (CMS) Reports Finalizing 2027 Medicare Advantage and Part D Payment Policies Saying it Strengthens Accountability and Long-Term Sustainability https://t.co/3nqV9lpVUS

— SIERRA SUN TIMES link

.

The conventional wisdom might be that a temporary program ending is just... a program ending. But for seniors navigating the already complex landscape of Medicare, this premature conclusion of the stabilization demonstration is a direct signal of potential premium increases. AARP highlights that original Medicare enrollees could face higher monthly premiums for their standalone Part D drug plans now that this pilot program is being discontinued

"Original Medicare enrollees could face higher monthly premiums for their stand-alone Part D drug plan coverage next year now that a pilot program designed to keep premiums in check will be discontinued."

. This isn't just abstract policy; it translates to real dollars. For someone on a fixed income, even a modest increase in their monthly drug plan premium can mean difficult choices between medications, groceries, or other essential living expenses. The CMS itself acknowledged the demonstration was implemented 'to address volatility and variation in standalone premiums'

"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."

, indicating that without it, such variations are expected to return or worsen.

The termination of the Part D Premium Stabilization Demonstration could have consequences far beyond just the monthly premium amount. When premiums become less predictable or significantly higher, it can force seniors to re-evaluate their plan choices annually. This might lead to a less stable market for PDPs, potentially reducing the number of plans available or pushing insurers to implement more aggressive cost-control measures, often referred to by the industry as 'utilization management' – a phrase that means roughly the same thing as 'no.' The CMS's broader announcement about finalizing 2027 MA and Part D payment policies aims to improve 'payment accuracy and competition'

Today, CMS released the Calendar Year 2027 Medicare Advantage (MA) and Part D Rate Announcement to improve payment accuracy and competition across both programs. The finalized policies also advance CMS’ vision of a sustainable and stable MA program that offers high-quality…

— CMSGov link

, but the early end of a program that *stabilized* costs seems counterintuitive to fostering choice and affordability for beneficiaries.